<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet13246</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-13246</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Urinary C Peptide/ Creatinine Ratio Is Related to Insulin Resistance but Not Vascular Complications In Type 2 Diabetes</article-title><trans-title-group xml:lang="en"><trans-title>Urinary C Peptide/ Creatinine Ratio Is Related to Insulin Resistance but Not Vascular Complications In Type 2 Diabetes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Eman</surname><given-names>Y. M.</given-names></name><name name-style="western" xml:lang="en"><surname>Eman</surname><given-names>Y. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Eman Y Morsy, PhD, Professor</p><p>Alexandria</p></bio><bio xml:lang="en"><p>Eman Y. Morsy, PhD, Professor </p><p>Alexandria </p></bio><email xlink:type="simple">Dr.emanyoussef@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8225-5052</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Noha</surname><given-names>G. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Noha</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Noha G Amin , PhD, Professor</p><p>Alexandria</p></bio><bio xml:lang="en"><p>Noha G. Amin, PhD, Professor </p><p>Alexandria </p></bio><email xlink:type="simple">Noha.gaber@alexmed.edu.eg</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Yasmine</surname><given-names>A. I.</given-names></name><name name-style="western" xml:lang="en"><surname>Yasmine</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Yasmine A. Issa, PhD, Professor </p><p>New Alamein</p></bio><bio xml:lang="en"><p>Yasmine A. Issa, PhD, Professor</p><p>New Alamein  </p></bio><email xlink:type="simple">yasmineissa@aast.edu</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Rowan</surname><given-names>K.A.K.</given-names></name><name name-style="western" xml:lang="en"><surname>Rowan</surname><given-names>K.A.K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Rowan KA Khalifa, MD, Doctor</p><p>Alexandria</p></bio><bio xml:lang="en"><p>Rowan K.A. Khalifa, MD, Doctor </p><p>Alexandria</p></bio><email xlink:type="simple">Rowan.khalifa210@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5463-7926</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Heba</surname><given-names>S. K.</given-names></name><name name-style="western" xml:lang="en"><surname>Heba</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Heba S Kassab, MD PhD, Assistant Professor</p><p>Web of Science Researcher ID: GRT-0147 -2022; Scopus ID: 57188661935</p><p>17 Champollion Street, El Messallah, Alexandria, postcode 21131</p></bio><bio xml:lang="en"><p>Heba S. Kassab, MD PhD, Assistant Professor </p><p>Web of Science Researcher ID: GRT-0147 -2022; Scopus ID: 57188661935</p><p>17 Champollion Street, El Messallah, Alexandria, postcode 21131 </p></bio><email xlink:type="simple">heba.kassab@alexmed.edu.eg</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Egypt</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Associate Professor of Medical Biochemistry, College of Medicine, Arab Academy of Science, Technology and Maritime Transport</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Associate Professor of Medical Biochemistry, College of Medicine, Arab Academy of Science, Technology and Maritime Transport</institution><country>Egypt</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Department of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Department of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Egypt</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Assistant Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Assistant Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University</institution><country>Egypt</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>07</month><year>2026</year></pub-date><volume>23</volume><issue>2</issue><fpage>61</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Eman Y.M., Noha G.A., Yasmine A.I., Rowan K., Heba S.K., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Eman Y.M., Noha G.A., Yasmine A.I., Rowan K., Heba S.K.</copyright-holder><copyright-holder xml:lang="en">Eman Y.M., Noha G.A., Yasmine A.I., Rowan K., Heba S.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/13246">https://www.omet-endojournals.ru/jour/article/view/13246</self-uri><abstract><sec><title>BACKGROUND</title><p>BACKGROUND. Insulin resistance (IR) is considered the main mechanism of type 2 diabetes (T2DM). Diabetic vascular complications (DVC) are main causes of morbidity and mortality. Urinary c-peptide to creatinine ratio (UCPCR) is a novel promising biomarker that may be of value in assessment of IR and DVC.</p></sec><sec><title>AIM</title><p>AIM. The present work aimed at studying the relation between UCPCR, IR and DVC in subjects with T2DM.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. This was a cross-sectional study performed on a group of subjects with T2DM. Insulin resistance was assessed by measuring homeostasis model assessment for insulin resistance (HOMA-IR). Laboratory investigations included glycemic parameters and renal functions. Human C-peptide ELISA kit was used to asses c-peptide level in a spot urine sample after processing.</p></sec><sec><title>RESULTS</title><p>RESULTS. The study included 90 subjects with T2DM. There was highly statistically significant positive correlations between UCPCR and HOMA-IR, FPG and HbA1c with P values of &lt;0.001, 0.006 and 0.005 respectively. FPG, HbA1c, and UCPCR were the independent risk factors for IR in the univariate regression analysis. However, UCPCR was the only independent risk factor for IR in multivariate analysis (OR 16.431(1.401–192.706). UCPCR cut-off value (&gt;0.19) nmol/mmol was able to differentiate significantly (p&lt;0.001) between patients with IR and those without IR with good sensitivity, specificity and AUC (85.11%, 60.47% and 0.716 respectively).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. In patients with T2DM, UCPCR could be used as a simple, noninvasive and available biomarker for IR. It also could be used as a marker of glycemic control. However, UCPCR is not related to DVC.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND. Insulin resistance (IR) is considered the main mechanism of type 2 diabetes (T2DM). Diabetic vascular complications (DVC) are main causes of morbidity and mortality. Urinary c-peptide to creatinine ratio (UCPCR) is a novel promising biomarker that may be of value in assessment of IR and DVC.</p></sec><sec><title>AIM</title><p>AIM. The present work aimed at studying the relation between UCPCR, IR and DVC in subjects with T2DM.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. This was a cross-sectional study performed on a group of subjects with T2DM. Insulin resistance was assessed by measuring homeostasis model assessment for insulin resistance (HOMA-IR). Laboratory investigations included glycemic parameters and renal functions. Human C-peptide ELISA kit was used to asses c-peptide level in a spot urine sample after processing.</p></sec><sec><title>RESULTS</title><p>RESULTS. The study included 90 subjects with T2DM. There was highly statistically significant positive correlations between UCPCR and HOMA-IR, FPG and HbA1c with P values of &lt;0.001, 0.006 and 0.005 respectively. FPG, HbA1c, and UCPCR were the independent risk factors for IR in the univariate regression analysis. However, UCPCR was the only independent risk factor for IR in multivariate analysis (OR 16.431(1.401–192.706). UCPCR cut-off value (&gt;0.19) nmol/mmol was able to differentiate significantly (p&lt;0.001) between patients with IR and those without IR with good sensitivity, specificity and AUC (85.11%, 60.47% and 0.716 respectively).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. In patients with T2DM, UCPCR could be used as a simple, noninvasive and available biomarker for IR. It also could be used as a marker of glycemic control. However, UCPCR is not related to DVC.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>urinary c-peptide to creatinine ratio</kwd><kwd>insulin resistance</kwd><kwd>type 2 diabetes</kwd><kwd>diabetic vascular complications</kwd></kwd-group><kwd-group xml:lang="en"><kwd>urinary c-peptide to creatinine ratio</kwd><kwd>insulin resistance</kwd><kwd>type 2 diabetes</kwd><kwd>diabetic vascular complications</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015;1(1):1-22. doi: https://doi.org/10.1038/nrdp.2015.19.</mixed-citation><mixed-citation xml:lang="en">DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015;1(1):1-22. doi: https://doi.org/10.1038/nrdp.2015.19.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Viner R, Segal T, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Archives of disease in childhood. 2005;90(1):10-4. doi: https://doi.org/10.1136/adc.2003.036467</mixed-citation><mixed-citation xml:lang="en">Viner R, Segal T, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Archives of disease in childhood. 2005;90(1):10-4. doi: https://doi.org/10.1136/adc.2003.036467</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cho M, Park JS, Nam J, et al. Association of abdominal obesity with atherosclerosis in type 2 diabetes mellitus (T2DM) in Korea. Journal of Korean medical science. 2008;23(5):781-8. doi: https://doi.org/10.3346/jkms.2008.23.5.781</mixed-citation><mixed-citation xml:lang="en">Cho M, Park JS, Nam J, et al. Association of abdominal obesity with atherosclerosis in type 2 diabetes mellitus (T2DM) in Korea. Journal of Korean medical science. 2008;23(5):781-8. doi: https://doi.org/10.3346/jkms.2008.23.5.781</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The lancet. 2017;389(10085):2239-51. doi: https://doi.org/10.1016/S0140-6736(17)30539-1</mixed-citation><mixed-citation xml:lang="en">Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The lancet. 2017;389(10085):2239-51. doi: https://doi.org/10.1016/S0140-6736(17)30539-1</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology-Endocrinology and Metabolism. 1979;237(3):E214. doi: https://doi.org/10.1152/ajpendo.1979.237.3.E214</mixed-citation><mixed-citation xml:lang="en">DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology-Endocrinology and Metabolism. 1979;237(3):E214. doi: https://doi.org/10.1152/ajpendo.1979.237.3.E214</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: http://dx.doi.org/10.18535/jmscr/v4i9.65</mixed-citation><mixed-citation xml:lang="en">Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: http://dx.doi.org/10.18535/jmscr/v4i9.65</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jones AG, Besser R, McDonald TJ, et al. Urine C‐peptide creatinine ratio is an alternative to stimulated serum C‐peptide measurement in late‐onset, insulin‐treated diabetes. Diabetic medicine. 2011;28(9):1034-8. doi: https://doi.org/10.1111/j.1464-5491.2011.03272.x</mixed-citation><mixed-citation xml:lang="en">Jones AG, Besser R, McDonald TJ, et al. Urine C‐peptide creatinine ratio is an alternative to stimulated serum C‐peptide measurement in late‐onset, insulin‐treated diabetes. Diabetic medicine. 2011;28(9):1034-8. doi: https://doi.org/10.1111/j.1464-5491.2011.03272.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Zou X, Cai X, et al. Urinary C‐peptide/creatinine ratio: a useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. Journal of Diabetes. 2021;13(11):893-904. doi: https://doi.org/10.1111/1753-0407.13203</mixed-citation><mixed-citation xml:lang="en">Wang Y, Zou X, Cai X, et al. Urinary C‐peptide/creatinine ratio: a useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. Journal of Diabetes. 2021;13(11):893-904. doi: https://doi.org/10.1111/1753-0407.13203</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Alshamsi F, Pathan A, Yasin J, et al. Urinary C-peptide creatinine ratio as a non-invasive diagnostic tool for differentiating type 1 from type 2 diabetes mellitus in adult Emirati population: a prospective validation study. Front Endocrinol (Lausanne). 2025;16:1687920. doi: https://doi.org/10.3389/fendo.2025.1687920.</mixed-citation><mixed-citation xml:lang="en">Alshamsi F, Pathan A, Yasin J, et al. Urinary C-peptide creatinine ratio as a non-invasive diagnostic tool for differentiating type 1 from type 2 diabetes mellitus in adult Emirati population: a prospective validation study. Front Endocrinol (Lausanne). 2025;16:1687920. doi: https://doi.org/10.3389/fendo.2025.1687920.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Irilouzadian R, Afaghi S, Esmaeili Tarki F, et al. Urinary c-peptide creatinine ratio (UCPCR) as a predictor of coronary artery disease in type 1 diabetes mellitus. Endocrinol Diabetes Metab. 2023;6(3):e413. doi: https://doi.org/10.1002/edm2.413</mixed-citation><mixed-citation xml:lang="en">Irilouzadian R, Afaghi S, Esmaeili Tarki F, et al. Urinary c-peptide creatinine ratio (UCPCR) as a predictor of coronary artery disease in type 1 diabetes mellitus. Endocrinol Diabetes Metab. 2023;6(3):e413. doi: https://doi.org/10.1002/edm2.413</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Consultation WE. Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation Geneva: World Health Organization. 2008;2008:8-11</mixed-citation><mixed-citation xml:lang="en">Consultation WE. Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation Geneva: World Health Organization. 2008;2008:8-11</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. Journal of health economics. 2008;27(2):519-29. doi: https://doi.org/10.1016/j.jhealeco.2007.05.005</mixed-citation><mixed-citation xml:lang="en">Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. Journal of health economics. 2008;27(2):519-29. doi: https://doi.org/10.1016/j.jhealeco.2007.05.005</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S252-S265. doi: https://doi.org/10.2337/dc25-S012</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S252-S265. doi: https://doi.org/10.2337/dc25-S012</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McDermott MM, Criqui MH, Liu K, et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. Journal of Vascular Surgery. 2000;32(6):1164-71. doi: https://doi.org/10.1067/mva.2000.108640</mixed-citation><mixed-citation xml:lang="en">McDermott MM, Criqui MH, Liu K, et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. Journal of Vascular Surgery. 2000;32(6):1164-71. doi: https://doi.org/10.1067/mva.2000.108640</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ziaee A, Esmailzadehha N, Oveisi S, et al. The threshold value of homeostasis model assessment for insulin resistance in Qazvin metabolic diseases study (QMDS): assessment of metabolic syndrome. J Res Health Sci 2015;15:94–100</mixed-citation><mixed-citation xml:lang="en">Ziaee A, Esmailzadehha N, Oveisi S, et al. The threshold value of homeostasis model assessment for insulin resistance in Qazvin metabolic diseases study (QMDS): assessment of metabolic syndrome. J Res Health Sci 2015;15:94–100</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association Professional Practice Committee; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care.2025; 48 (Supplement_1): S239–S251. doi: https://doi.org/10.2337/dc25-S011.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association Professional Practice Committee; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care.2025; 48 (Supplement_1): S239–S251. doi: https://doi.org/10.2337/dc25-S011.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">McDonald TJ, Knight BA, Shields BM, et al. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clinical chemistry. 2009;55(11):2035-9. doi: https://doi.org/10.1373/clinchem.2009.129312</mixed-citation><mixed-citation xml:lang="en">McDonald TJ, Knight BA, Shields BM, et al. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clinical chemistry. 2009;55(11):2035-9. doi: https://doi.org/10.1373/clinchem.2009.129312</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Gao Y, Cai X, et al. Clinical implications of urinary C‐peptide creatinine ratio in patients with different types of diabetes. Journal of Diabetes Research. 2019;2019(1):1747684. doi: https://doi.org/10.1155/2019/1747684</mixed-citation><mixed-citation xml:lang="en">Wang Y, Gao Y, Cai X, et al. Clinical implications of urinary C‐peptide creatinine ratio in patients with different types of diabetes. Journal of Diabetes Research. 2019;2019(1):1747684. doi: https://doi.org/10.1155/2019/1747684</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Besser RE, Shields BM, Hammersley SE, et al. Home urine C‐ peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatric diabetes. 2013;14(3):181-8. doi: https://doi.org/10.1111/pedi.12008</mixed-citation><mixed-citation xml:lang="en">Besser RE, Shields BM, Hammersley SE, et al. Home urine C‐ peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatric diabetes. 2013;14(3):181-8. doi: https://doi.org/10.1111/pedi.12008</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou W, Li J, Yuan X, et al. Application of urine C-peptide creatinine ratio in type 2 diabetic patients with different levels of renal function. Frontiers in Endocrinology. 2022;13:1052794. doi: https://doi.org/10.3389/fendo.2022.1052794</mixed-citation><mixed-citation xml:lang="en">Zhou W, Li J, Yuan X, et al. Application of urine C-peptide creatinine ratio in type 2 diabetic patients with different levels of renal function. Frontiers in Endocrinology. 2022;13:1052794. doi: https://doi.org/10.3389/fendo.2022.1052794</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: https://doi.org/http://dx.doi.org/10.18535/jmscr/v4i9.65</mixed-citation><mixed-citation xml:lang="en">Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: https://doi.org/http://dx.doi.org/10.18535/jmscr/v4i9.65</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Reintar S, Pöchhacker M, Obermayer A, et al. Urinary C-Peptide to Creatinine Ratio (UCPCR) as Indicator for Metabolic Risk in Apparently Healthy Adults—A BioPersMed Cohort Study. Nutrients. 2023;15(9):2073. doi: https://doi.org/10.3390/nu15092073</mixed-citation><mixed-citation xml:lang="en">Reintar S, Pöchhacker M, Obermayer A, et al. Urinary C-Peptide to Creatinine Ratio (UCPCR) as Indicator for Metabolic Risk in Apparently Healthy Adults—A BioPersMed Cohort Study. Nutrients. 2023;15(9):2073. doi: https://doi.org/10.3390/nu15092073</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Oram RA, Rawlingson A, Shields BM, et al. Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ open. 2013;3(12):e003193. doi: https://doi.org/10.1136/bmjopen-2013-003193</mixed-citation><mixed-citation xml:lang="en">Oram RA, Rawlingson A, Shields BM, et al. Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ open. 2013;3(12):e003193. doi: https://doi.org/10.1136/bmjopen-2013-003193</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gedam M, Sarma D, Choudhury B. Urinary C-peptide Creatinine Ratio and Its Correlation with Parameters of Metabolic Syndrome. Journal of Endocrinology Research. 2021;3(2):1-9. doi: https://doi.org/10.30564/JER.V3I2.3451</mixed-citation><mixed-citation xml:lang="en">Gedam M, Sarma D, Choudhury B. Urinary C-peptide Creatinine Ratio and Its Correlation with Parameters of Metabolic Syndrome. Journal of Endocrinology Research. 2021;3(2):1-9. doi: https://doi.org/10.30564/JER.V3I2.3451</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan AA, Elshall S, Erfan A, et al. Urinary C-peptide and urinary C-peptide creatinine ratio as markers for insulin resistance in obese children and adolescents. Pediatric Research. 2022;92(3):805-9. doi: https://doi.org/10.1038/s41390-021-01847-2</mixed-citation><mixed-citation xml:lang="en">Hassan AA, Elshall S, Erfan A, et al. Urinary C-peptide and urinary C-peptide creatinine ratio as markers for insulin resistance in obese children and adolescents. Pediatric Research. 2022;92(3):805-9. doi: https://doi.org/10.1038/s41390-021-01847-2</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Farghaly HS, Metwalley KA, Gamal Y, Saied GM, Farouk Y. Urinary C-peptide creatinine ratio is a significant indicator of non-alcoholic fatty liver disease in children with obesity. The Turkish Journal of Pediatrics. 2022;64(3):482-9. doi: https://doi.org/10.24953/turkjped.2022.41</mixed-citation><mixed-citation xml:lang="en">Farghaly HS, Metwalley KA, Gamal Y, Saied GM, Farouk Y. Urinary C-peptide creatinine ratio is a significant indicator of non-alcoholic fatty liver disease in children with obesity. The Turkish Journal of Pediatrics. 2022;64(3):482-9. doi: https://doi.org/10.24953/turkjped.2022.41</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kulkarni C, Patil S. Urinary C-Peptide and urine C-pentide/ Creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects-a randomized study. 2016. doi: https://doi.org/10.22376/IJPBS.2016.7.4.B443-446</mixed-citation><mixed-citation xml:lang="en">Kulkarni C, Patil S. Urinary C-Peptide and urine C-pentide/ Creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects-a randomized study. 2016. doi: https://doi.org/10.22376/IJPBS.2016.7.4.B443-446</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Elzahar W, Arafa A, Youssef A, Erfan A, El Amrousy D. Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients. European Journal of Pediatrics. 2020;179:1115-20. doi: https://doi.org/10.1007/s00431-020-03606-7</mixed-citation><mixed-citation xml:lang="en">Elzahar W, Arafa A, Youssef A, Erfan A, El Amrousy D. Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients. European Journal of Pediatrics. 2020;179:1115-20. doi: https://doi.org/10.1007/s00431-020-03606-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
